Arkuda Therapeutics
Michael Esposito serves as Vice President of Finance at Arkuda Therapeutics since May 2022. Prior experience includes roles as Executive Director and Controller at CRISPR Therapeutics from July 2016 to May 2022 and Senior Director of Finance and Controller at FORUM Pharmaceuticals from January 2011 to July 2016. Previous positions include Director of Finance at Aarvon Biosciences, Baxter Healthcare, and Epic Therapeutics, Inc., as well as a finance role at Ares Serono and Supervisor at KPMG Peat Marwick. Michael Esposito holds a Master’s degree in Finance from Suffolk University and a Bachelor’s degree in Accounting from Boston College.
This person is not in any teams
This person is not in any offices
Arkuda Therapeutics
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.